Paul H. Ratner

4.0k total citations
93 papers, 2.7k citations indexed

About

Paul H. Ratner is a scholar working on Immunology and Allergy, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Paul H. Ratner has authored 93 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Immunology and Allergy, 78 papers in Physiology and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul H. Ratner's work include Allergic Rhinitis and Sensitization (83 papers), Asthma and respiratory diseases (78 papers) and Respiratory and Cough-Related Research (37 papers). Paul H. Ratner is often cited by papers focused on Allergic Rhinitis and Sensitization (83 papers), Asthma and respiratory diseases (78 papers) and Respiratory and Cough-Related Research (37 papers). Paul H. Ratner collaborates with scholars based in United States, Bulgaria and Bangladesh. Paul H. Ratner's co-authors include Frank C. Hampel, Eli O. Meltzer, Julius van Bavel, Craig LaForce, Steven R. Findlay, Jay Grossman, George Philip, Theodore F. Reiss, David Day and Ambarish J. Ambegaonkar and has published in prestigious journals such as PEDIATRICS, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Paul H. Ratner

91 papers receiving 2.5k citations

Peers

Paul H. Ratner
Michael J. Kraemer United States
CG Lofdahl Sweden
Mascha K. Rochat Switzerland
Ian Naya United Kingdom
Paul H. Ratner
Citations per year, relative to Paul H. Ratner Paul H. Ratner (= 1×) peers Pinja Ilmarinen

Countries citing papers authored by Paul H. Ratner

Since Specialization
Citations

This map shows the geographic impact of Paul H. Ratner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul H. Ratner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul H. Ratner more than expected).

Fields of papers citing papers by Paul H. Ratner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul H. Ratner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul H. Ratner. The network helps show where Paul H. Ratner may publish in the future.

Co-authorship network of co-authors of Paul H. Ratner

This figure shows the co-authorship network connecting the top 25 collaborators of Paul H. Ratner. A scholar is included among the top collaborators of Paul H. Ratner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul H. Ratner. Paul H. Ratner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ratner, Paul H., Charles P. Andrews, Frank C. Hampel, et al.. (2017). Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy Asthma and Clinical Immunology. 13(1). 18–18. 23 indexed citations
2.
Andrews, Charles P., et al.. (2013). The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis. Annals of Allergy Asthma & Immunology. 111(1). 9–13. 9 indexed citations
4.
Kaliner, Michael, et al.. (2011). The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Annals of Allergy Asthma & Immunology. 106(2). S6–S11. 26 indexed citations
5.
Hampel, Frank C., Paul H. Ratner, Julius van Bavel, et al.. (2010). Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Annals of Allergy Asthma & Immunology. 105(2). 168–173. 93 indexed citations
6.
Hampel, Frank C., et al.. (2010). Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy and Asthma Proceedings. 31(4). 290–295. 23 indexed citations
7.
Ratner, Paul H., Eli O. Meltzer, & Ariel Teper. (2009). Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. International Journal of Pediatric Otorhinolaryngology. 73(5). 651–657. 47 indexed citations
8.
Kim, Kenneth, Ruediger Nave, Paul H. Ratner, et al.. (2007). Safety of Once-Daily Ciclesonide Nasal Spray in Children 2 to 5 Years of Age with Perennial Allergic Rhinitis. Pediatric Asthma Allergy & Immunology. 20(4). 229–242. 14 indexed citations
9.
Ratner, Paul H., Patrick Darken, Mark A. Wingertzahn, & Tushar Shah. (2007). Ciclesonide and Beclomethasone Dipropionate Coadministration: Effect on Cortisol in Perennial Allergic Rhinitis. Journal of Asthma. 44(8). 629–633. 6 indexed citations
10.
Hampel, Frank C., Paul H. Ratner, Niran J. Amar, et al.. (2006). Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. Allergy and Asthma Proceedings. 27(3). 202–207. 12 indexed citations
11.
Ratner, Paul H., et al.. (2006). Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 97(5). 657–663. 25 indexed citations
12.
Santanello, Nancy C., Carla DeMuro‐Mercon, Shailen Shah, et al.. (2006). Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis. Allergy and Asthma Proceedings. 27(3). 231–239. 9 indexed citations
13.
Meltzer, Eli O., Frank C. Hampel, Paul H. Ratner, et al.. (2005). Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 95(6). 600–606. 37 indexed citations
14.
Philip, George, K. Malmström, Frank C. Hampel, et al.. (2002). Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring. Clinical & Experimental Allergy. 32(7). 1020–1028. 195 indexed citations
15.
Ratner, Paul H., et al.. (2000). Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 105(6). 1101–1107. 32 indexed citations
16.
Dockhorn, Robert J., Donald W. Aaronson, Paul Chervinsky, et al.. (1999). Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis. Annals of Allergy Asthma & Immunology. 82(4). 349–359. 43 indexed citations
17.
Ratner, Paul H., et al.. (1994). A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 94(5). 818–825. 56 indexed citations
18.
Meltzer, Eli O., H.Alice Orgel, Edwin A. Bronsky, et al.. (1992). Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: A study of its effect on their symptoms, quality of life, and nasal cytology. Journal of Allergy and Clinical Immunology. 90(2). 242–249. 56 indexed citations
19.
As, Andre van, et al.. (1991). Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis.. PubMed. 67(2 Pt 1). 156–62. 48 indexed citations
20.
Kemp, James P., Edwin A. Bronsky, Jay Grossman, et al.. (1989). Albuterol treatment for children with asthma: A comparison of inhaled powder and aerosol. Journal of Allergy and Clinical Immunology. 83(3). 697–702. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026